Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | Is it time to reconsider the locoregional approach in HER2+ breast cancer?

Philip Poortmans • 3 May 2022
ESMO Breast 2022
Breast Cancer

Philip Poortmans, MD, PhD, AZ Sint-Augustinus – Oncologisch Centrum GZA – Iridium Kankernetwerk, Antwerpen, Belgium, talks on whether treatment in early-stage HER2-positive breast cancer should be modified, highlighting de-escalation of locregional approaches. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

More from Philip Poortmans

2:41
Controversies and uncertainties in axillary management
Philip Poortmans • 16 Mar 2023
0:28
Controversies in the treatment of the axilla
Philip Poortmans • 16 Mar 2023
1:15
St. Gallen BCC 2023: translating clinical developments
Philip Poortmans • 16 Mar 2023
1:27
PRADA: evaluating radiotherapy before deep inferior flap reconstruction
Philip Poortmans • 3 May 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals